Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler’s pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape.Prescription & OTC DrugsOur pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation.Infectious Disease TreatmentsSterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases.Generic Drug DevelopmentWe work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Firm News

February 6, 2026

Sterne Kessler Recognized as a Top Patent Firm by Juristat

Sterne, Kessler, Goldstein & Fox

Speaking Engagement

January 21, 2026 12:00 AM – 12:00 AM PST

Pharma & Biotech Patent Litigation Conference

Firm News

November 10, 2025

Sterne Kessler Recognized in the 2026 Best Law Firms Rankings

Sterne, Kessler, Goldstein & Fox

Articles

October 22, 2025

Obviousness-Type Double Patenting

Sterne, Kessler, Goldstein & Fox

Articles

October 22, 2025

Small Entity Status for Life Sciences Companies — Determining Number of Employees

Sterne, Kessler, Goldstein & Fox

Articles

October 22, 2025

Trademark Strategies for Life Sciences Companies

Sterne, Kessler, Goldstein & Fox